Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

This study is testing a combination of tepotinib (a targeted drug blocking a cancer growth signal called MET) and paclitaxel (a standard chemotherapy) in patients with advanced stomach or gastroesophageal junction (GEJ) cancer that has a specific genetic change — MET amplification or MET exon 14 skipping mutation. These genetic changes make some cancers dependent on the MET pathway for growth. **You may be eligible if:** - You are 19 or older - You have advanced or metastatic stomach or GEJ cancer confirmed by biopsy - Your cancer has a MET amplification or MET exon 14 mutation (confirmed by testing) - Your cancer has progressed after first-line fluoropyrimidine-based chemotherapy **You may NOT be eligible if:** - Your cancer does not have the MET alteration required for the study - You have not yet tried first-line chemotherapy (for the Phase 2 portion) - Your health is too poor to tolerate the treatments Talk to your doctor to see if this trial is right for you.